Citations (55)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Carolina T. Orozco, Manuela Bersellini, Lorraine M. Irving, Wesley W. Howard, David Hargreaves, Paul W. A. Devine, Elise Siouve, Gareth J. Browne, Nicholas J. Bond, Jonathan J. Phillips, Peter Ravn & Sophie E. Jackson. (2022) Mechanistic insights into the rational design of masked antibodies. mAbs 14:1.
Read now
Read now
Rebecca P Chen, Kenta Shinoda, Pragya Rampuria, Fang Jin, Tin Bartholomew, Chunxia Zhao, Fan Yang & Javier Chaparro-Riggers. (2022) Bispecific antibodies for immune cell retargeting against cancer. Expert Opinion on Biological Therapy 22:8, pages 965-982.
Read now
Read now
W. Michael Kavanaugh. (2020) Antibody prodrugs for cancer. Expert Opinion on Biological Therapy 20:2, pages 163-171.
Read now
Read now
Alexis D. Leal, Anuradha Krishnamurthy, Lia Head & Wells A. Messersmith. (2018) Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer. Expert Opinion on Investigational Drugs 27:11, pages 901-916.
Read now
Read now
Mahendra P Deonarain, Gokhan Yahioglu, Ioanna Stamati & Jared Marklew. (2015) Emerging formats for next-generation antibody drug conjugates. Expert Opinion on Drug Discovery 10:5, pages 463-481.
Read now
Read now
Articles from other publishers (50)
Toan D. Nguyen, Brandon M. Bordeau & Joseph P. Balthasar. (2023) Use of Payload Binding Selectivity Enhancers to Improve Therapeutic Index of Maytansinoid–Antibody–Drug Conjugates. Molecular Cancer Therapeutics 22:11, pages 1332-1342.
Crossref
Crossref
Han Han, Lei Xing, Bi-Te Chen, Yang Liu, Tian-Jiao Zhou, Yi Wang, Ling-Feng Zhang, Ling Li, Chong-Su Cho & Hu-Lin Jiang. (2023) Progress on the pathological tissue microenvironment barrier-modulated nanomedicine. Advanced Drug Delivery Reviews 200, pages 115051.
Crossref
Crossref
Mengyu Li, Sen Mei, Yi Yang, Yuelei Shen & Lei Chen. (2022) Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspective. Antibody Therapeutics 5:3, pages 164-176.
Crossref
Crossref
Jonathan M. Labriola, Shane Miersch, Gang Chen, Chao Chen, Alevtina Pavlenco, Reza Saberianfar, Francesca Caccuri, Alberto Zani, Nitin Sharma, Annie Feng, Daisy W. Leung, Arnaldo Caruso, Giuseppe Novelli, Gaya K. Amarasinghe & Sachdev S. Sidhu. (2022) Peptide–Antibody Fusions Engineered by Phage Display Exhibit an Ultrapotent and Broad Neutralization of SARS-CoV-2 Variants. ACS Chemical Biology 17:7, pages 1978-1988.
Crossref
Crossref
Erwin R. BoghaertMegan C. Cox & Kedar S. Vaidya. (2022) Pathophysiologic and Pharmacologic Considerations to Improve the Design and Application of Antibody–Drug Conjugates. Cancer Research 82:10, pages 1858-1869.
Crossref
Crossref
Valentina Boni, Mary J. Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E. Sanborn, Randy F. Sweis, Patricia LoRusso, Misako Nagasaka, Javier Garcia-Corbacho, Shadia Jalal, James J. Harding, Stella K. Kim, Iris H.C. Miedema, Danielle J. Vugts, Marc C. Huisman, Gerben J.C. Zwezerijnen, Guus A.M.S. van Dongen, C. Willemien Menke van der Houven van Oordt, Song Wang, Tam Dang, Ivan A. Zein, Olga Vasiljeva, Susan K. Lyman, Virginia Paton, Alison Hannah & Joyce F. Liu. (2022) Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial. Clinical Cancer Research 28:10, pages 2020-2029.
Crossref
Crossref
Evanthia T. Roussos Torres & Leisha A. Emens. (2021) Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody–drug conjugates and bispecific antibodies. Breast Cancer Research and Treatment 191:2, pages 291-302.
Crossref
Crossref
Morse Faria, Varun Ramani & Seema Kumar. 2022. An Introduction to Bioanalysis of Biopharmaceuticals. An Introduction to Bioanalysis of Biopharmaceuticals
49
74
.
Dominique Lesuisse. 2022. Drug Delivery to the Brain. Drug Delivery to the Brain
27
69
.
Md Abdus Subhan & Vladimir P. Torchilin. (2021) Advances with antibody-drug conjugates in breast cancer treatment. European Journal of Pharmaceutics and Biopharmaceutics 169, pages 241-255.
Crossref
Crossref
Jungheun Hyun, Soyeong Jun, Hyeonseob Lim, Hyunjun Cho, Sung-Hwan You, Sang-Jun Ha, Jung-Joon Min & Duhee Bang. (2021)
Engineered Attenuated
Salmonella typhimurium
Expressing Neoantigen Has Anticancer Effects
. ACS Synthetic Biology 10:10, pages 2478-2487.
Crossref
Crossref
Bruce Howng, Michael B. Winter, Carol LePage, Irina Popova, Michael Krimm & Olga Vasiljeva. (2021) Novel Ex Vivo Zymography Approach for Assessment of Protease Activity in Tissues with Activatable Antibodies. Pharmaceutics 13:9, pages 1390.
Crossref
Crossref
Melissa Johnson, Anthony El-Khoueiry, Navid Hafez, Nehal Lakhani, Hirva Mamdani, Jordi Rodon, Rachel E. Sanborn, Javier Garcia-Corbacho, Valentina Boni, Mark Stroh, Alison L. Hannah, Song Wang, Henry Castro & Alexander Spira. (2021) Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies. Clinical Cancer Research 27:16, pages 4521-4530.
Crossref
Crossref
Adrian Elter, Desislava Yanakieva, David Fiebig, Kerstin Hallstein, Stefan Becker, Ulrich Betz & Harald Kolmar. (2021) Protease-Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity. Frontiers in Immunology 12.
Crossref
Crossref
Aung Naing, Fiona Thistlethwaite, Elisabeth G.E. De Vries, Ferry A.L.M. Eskens, Nataliya Uboha, Patrick A. Ott, Patricia LoRusso, Javier Garcia-Corbacho, Valentina Boni, Johanna Bendell, Karen A. Autio, Manreet Randhawa, Greg Durm, Marta Gil-Martin, Mark Stroh, Alison L. Hannah, Hendrik-Tobias Arkenau & Alexander Spira. (2021)
CX-072 (pacmilimab), a Probody
®
PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study
. Journal for ImmunoTherapy of Cancer 9:7, pages e002447.
Crossref
Crossref
Rachel E Sanborn, Omid Hamid, Elisabeth GE de Vries, Patrick A Ott, Javier Garcia-Corbacho, Valentina Boni, Johanna Bendell, Karen A Autio, Daniel C Cho, Ruth Plummer, Mark Stroh, Lawrence Lu & Fiona Thistlethwaite. (2021) CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study. Journal for ImmunoTherapy of Cancer 9:7, pages e002446.
Crossref
Crossref
E. A. Bocharova, N. I. Kopytina & Е. Е. Slynko. (2021) Anti-tumour drugs of marine origin currently at various stages of clinical trials (review). Regulatory Mechanisms in Biosystems 12:2, pages 265-280.
Crossref
Crossref
Xiaotian Zhong & Aaron M. D’Antona. (2021) Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics. Antibodies 10:2, pages 13.
Crossref
Crossref
Hwai Wen Chang, Gerhard Frey, Haizhen Liu, Charles Xing, Lawrence Steinman, William J. Boyle & Jay M. Short. (2021) Generating tumor-selective conditionally active biologic anti-CTLA4 antibodies via protein-associated chemical switches. Proceedings of the National Academy of Sciences 118:9.
Crossref
Crossref
Johanna Utterström, Sajjad Naeimipour, Robert Selegård & Daniel Aili. (2021) Coiled coil-based therapeutics and drug delivery systems. Advanced Drug Delivery Reviews 170, pages 26-43.
Crossref
Crossref
K. C. Nicolaou, Saiyong Pan, Kiran K. Pulukuri, Qiuji Ye, Stephan Rigol, Rohan D. Erande, Dionisios Vourloumis, Bogusław P. Nocek, Stefan Munneke, Joseph Lyssikatos, Amanda Valdiosera, Christine Gu, Baiwei Lin, Hetal Sarvaiaya, Jose Trinidad, Joseph Sandoval, Christina Lee, Mikhail Hammond, Monette Aujay, Nicole Taylor, Marybeth Pysz, James W. Purcell & Julia Gavrilyuk. (2021) Design, Synthesis, and Biological Evaluation of Tubulysin Analogues, Linker-Drugs, and Antibody–Drug Conjugates, Insights into Structure–Activity Relationships, and Tubulysin–Tubulin Binding Derived from X-ray Crystallographic Analysis. The Journal of Organic Chemistry 86:4, pages 3377-3421.
Crossref
Crossref
Mathilde Lorscheider, Alice Gaudin, Jessica Nakhlé, Kadi-Liis Veiman, Joël Richard & Christophe Chassaing. (2021) Challenges and opportunities in the delivery of cancer therapeutics: update on recent progress. Therapeutic Delivery 12:1, pages 55-76.
Crossref
Crossref
Ava P. Soleimany, Jesse D. Kirkpatrick, Susan Su, Jaideep S. Dudani, Qian Zhong, Ahmet Bekdemir & Sangeeta N. Bhatia. (2021)
Activatable Zymography Probes Enable
In Situ
Localization of Protease Dysregulation in Cancer
. Cancer Research 81:1, pages 213-224.
Crossref
Crossref
Jessica C. Graham, Jedd Hillegass & Gene Schulze. (2020) Considerations for setting occupational exposure limits for novel pharmaceutical modalities. Regulatory Toxicology and Pharmacology 118, pages 104813.
Crossref
Crossref
Ling Li, Zhen Yang & Xiaoyuan Chen. (2020) Recent Advances in Stimuli-Responsive Platforms for Cancer Immunotherapy. Accounts of Chemical Research 53:10, pages 2044-2054.
Crossref
Crossref
Valentina Boni, Manish R. Sharma & Amita Patnaik. (2020) The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads. American Society of Clinical Oncology Educational Book:40, pages e58-e74.
Crossref
Crossref
Karen A. Autio, Valentina Boni, Rachel W. Humphrey & Aung Naing. (2020) Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology. Clinical Cancer Research 26:5, pages 984-989.
Crossref
Crossref
Vivian H. Trang, Xinqun Zhang, Roma C. Yumul, Weiping Zeng, Ivan J. Stone, Serena W. Wo, Melissa M. Dominguez, Julia H. Cochran, Jessica K. Simmons, Maureen C. Ryan, Robert P. Lyon, Peter D. Senter & Matthew R. Levengood. (2019) A coiled-coil masking domain for selective activation of therapeutic antibodies. Nature Biotechnology 37:7, pages 761-765.
Crossref
Crossref
David J. Newman. (2019) The “Utility” of Highly Toxic Marine-Sourced Compounds. Marine Drugs 17:6, pages 324.
Crossref
Crossref
Robbie G. Majzner, Johanna L. Theruvath, Anandani Nellan, Sabine Heitzeneder, Yongzhi Cui, Christopher W. Mount, Skyler P. Rietberg, Miles H. Linde, Peng Xu, Christopher Rota, Elena Sotillo, Louai Labanieh, Daniel W. Lee, Rimas J. Orentas, Dimiter S. Dimitrov, Zhongyu Zhu, Brad St Croix, Alberto Delaidelli, Alla Sekunova, Ezio Bonvini, Siddhartha S. Mitra, Martha M. Quezado, Ravindra Majeti, Michelle Monje, Poul H.B. Sorensen, John M. Maris & Crystal L. Mackall. (2019) CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clinical Cancer Research 25:8, pages 2560-2574.
Crossref
Crossref
Douglas Leipold & Saileta Prabhu. (2018) Pharmacokinetic and Pharmacodynamic Considerations in the Design of Therapeutic Antibodies. Clinical and Translational Science 12:2, pages 130-139.
Crossref
Crossref
Diego Ellerman. (2019) Bispecific T-cell engagers: Towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety. Methods 154, pages 102-117.
Crossref
Crossref
Ying Fu & Mitchell Ho. (2018) DNA damaging agent-based antibody-drug conjugates for cancer therapy. Antibody Therapeutics 1:2, pages 43-53.
Crossref
Crossref
K. C. Nicolaou, Rohan D. Erande, Jun Yin, Dionisios Vourloumis, Monette Aujay, Joseph Sandoval, Stefan Munneke & Julia Gavrilyuk. (2018) Improved Total Synthesis of Tubulysins and Design, Synthesis, and Biological Evaluation of New Tubulysins with Highly Potent Cytotoxicities against Cancer Cells as Potential Payloads for Antibody–Drug Conjugates. Journal of the American Chemical Society 140:10, pages 3690-3711.
Crossref
Crossref
John W. Hickey, Alyssa K. Kosmides & Jonathan P. Schneck. 2018. Biology of T Cells - Part A. Biology of T Cells - Part A
277
362
.
William R. Strohl. (2017) Current progress in innovative engineered antibodies. Protein & Cell 9:1, pages 86-120.
Crossref
Crossref
Olivier Marcq. 2018. Innovations for Next-Generation Antibody-Drug Conjugates. Innovations for Next-Generation Antibody-Drug Conjugates
113
161
.
Magali Guffroy, Hadi Falahatpisheh & Martin Finkelstein. 2018. Innovations for Next-Generation Antibody-Drug Conjugates. Innovations for Next-Generation Antibody-Drug Conjugates
45
71
.
Jack Lin & Jason Sagert. 2018. Innovations for Next-Generation Antibody-Drug Conjugates. Innovations for Next-Generation Antibody-Drug Conjugates
281
298
.
Feng Tian, Dowdy Jackson & Yun Bai. 2018. Innovations for Next-Generation Antibody-Drug Conjugates. Innovations for Next-Generation Antibody-Drug Conjugates
241
265
.
Felix S. Lichtenegger, Christina Krupka, Sascha Haubner, Thomas Köhnke & Marion Subklewe. (2017) Recent developments in immunotherapy of acute myeloid leukemia. Journal of Hematology & Oncology 10:1.
Crossref
Crossref
K. C. Nicolaou, Pengxi Chen, Shugao Zhu, Quan Cai, Rohan D. Erande, Ruofan Li, Hongbao Sun, Kiran Kumar Pulukuri, Stephan Rigol, Monette Aujay, Joseph Sandoval & Julia Gavrilyuk. (2017) Streamlined Total Synthesis of Trioxacarcins and Its Application to the Design, Synthesis, and Biological Evaluation of Analogues Thereof. Discovery of Simpler Designed and Potent Trioxacarcin Analogues. Journal of the American Chemical Society 139:43, pages 15467-15478.
Crossref
Crossref
Daniel E. Salazar & Glenn Gormley. 2017. Clinical and Translational Science. Clinical and Translational Science
719
743
.
Peter Ellmark, Sara M. Mangsbo, Christina Furebring, Per Norlén & Thomas H. Tötterman. (2016) Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation. Cancer Immunology, Immunotherapy 66:1, pages 1-7.
Crossref
Crossref
Amy Q. Han & William C. Olson. 2016. Antibody-Drug Conjugates. Antibody-Drug Conjugates
473
503
.
Boning Liu, Huaizu Guo, Junjie Zhang, Jingya Xue, Yun Yang, Ting Qin, Jin Xu, Qingcheng Guo, Dapeng Zhang, Weizhu Qian, Bohua Li, Sheng Hou, Jianxin Dai, Yajun Guo & Hao Wang. (2016) In-Depth Characterization of a Pro-Antibody–Drug Conjugate by LC–MS. Molecular Pharmaceutics 13:8, pages 2702-2710.
Crossref
Crossref
K. C. Nicolaou, Quan Cai, Hongbao Sun, Bo Qin & Shugao Zhu. (2016)
Total Synthesis of Trioxacarcins DC-45-A1, A, D, C, and C7″-
epi
-C and Full Structural Assignment of Trioxacarcin C
. Journal of the American Chemical Society 138:9, pages 3118-3124.
Crossref
Crossref
K. C. Nicolaou, Jun Yin, Debashis Mandal, Rohan D. Erande, Philipp Klahn, Michael Jin, Monette Aujay, Joseph Sandoval, Julia Gavrilyuk & Dionisios Vourloumis. (2016) Total Synthesis and Biological Evaluation of Natural and Designed Tubulysins. Journal of the American Chemical Society 138:5, pages 1698-1708.
Crossref
Crossref
Kinnari Pandya, Debra Wyatt, Brian Gallagher, Deep Shah, Andrew Baker, Jeffrey Bloodworth, Andrei Zlobin, Antonio Pannuti, Andrew Green, Ian O. Ellis, Aleksandra Filipovic, Jason Sagert, Ajay Rana, Kathy S. Albain, Lucio Miele, Mitchell F. Denning & Clodia Osipo. (2016) PKCα Attenuates Jagged-1–Mediated Notch Signaling in ErbB-2–Positive Breast Cancer to Reverse Trastuzumab Resistance. Clinical Cancer Research 22:1, pages 175-186.
Crossref
Crossref
Paola Mina-Osorio. (2015) Review: Basics of Drug Development in Rheumatology. Arthritis & Rheumatology 67:10, pages 2581-2590.
Crossref
Crossref